Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
Gal Cafri, … , Paul F. Robbins, Steven A. Rosenberg
Gal Cafri, … , Paul F. Robbins, Steven A. Rosenberg
Published October 5, 2020
Citation Information: J Clin Invest. 2020;130(11):5976-5988. https://doi.org/10.1172/JCI134915.
View: Text | PDF
Clinical Research and Public Health Oncology Article has an altmetric score of 103

mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

  • Text
  • PDF
Abstract

BACKGROUND Therapeutic vaccinations against cancer have mainly targeted differentiation antigens, cancer-testis antigens, and overexpressed antigens and have thus far resulted in little clinical benefit. Studies conducted by multiple groups have demonstrated that T cells recognizing neoantigens are present in most cancers and offer a specific and highly immunogenic target for personalized vaccination.METHODS We recently developed a process using tumor-infiltrating lymphocytes to identify the specific immunogenic mutations expressed in patients’ tumors. Here, validated, defined neoantigens, predicted neoepitopes, and mutations of driver genes were concatenated into a single mRNA construct to vaccinate patients with metastatic gastrointestinal cancer.RESULTS The vaccine was safe and elicited mutation-specific T cell responses against predicted neoepitopes not detected before vaccination. Furthermore, we were able to isolate and verify T cell receptors targeting KRASG12D mutation. We observed no objective clinical responses in the 4 patients treated in this trial.CONCLUSION This vaccine was safe, and potential future combination of such vaccines with checkpoint inhibitors or adoptive T cell therapy should be evaluated for possible clinical benefit in patients with common epithelial cancers.TRIAL REGISTRATION Phase I/II protocol (NCT03480152) was approved by the IRB committee of the NIH and the FDA.FUNDING Center for Clinical Research, NCI, NIH.

Authors

Gal Cafri, Jared J. Gartner, Tal Zaks, Kristen Hopson, Noam Levin, Biman C. Paria, Maria R. Parkhurst, Rami Yossef, Frank J. Lowery, Mohammad S. Jafferji, Todd D. Prickett, Stephanie L. Goff, Christine T. McGowan, Samantha Seitter, Mackenzie L. Shindorf, Anup Parikh, Praveen D. Chatani, Paul F. Robbins, Steven A. Rosenberg

×

Total citations by year

Year: 2025 2024 2023 2022 2021 Total
Citations: 18 53 66 59 30 226
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (226)

Title and authors Publication Year
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
Wang M, Yu F, Zhang Y
Molecular Cancer 2025
Leveraging mRNA technology for antigen based immuno-oncology therapies
Floudas CS, Sarkizova S, Ceccarelli M, Zheng W
Journal for Immunotherapy of Cancer 2025
Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens
Chen MH, Jiang J, Chen H, Wu RH, Xie W, Dai SZ, Zheng WP, Tan GH, Huang FY
Journal for Immunotherapy of Cancer 2025
Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects
Cheng Z, Huang H, Yin M, Liu H
Experimental Hematology & Oncology 2025
Cancer vaccines: current status and future directions
Zhou Y, Wei Y, Tian X, Wei X
Journal of Hematology & Oncology 2025
Adopting tomorrow’s therapies today: a perspective review of adoptive cell therapy in lung cancer
Abodunrin F, Olson DJ, Emehinola O, Bestvina CM
Therapeutic Advances in Medical Oncology 2025
Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy
Delgado-Almenta V, Blaya-Cánovas JL, Calahorra J, López-Tejada A, Griñán-Lisón C, Granados-Principal S
Pharmaceutics 2025
Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model
Nguyen CM, Vu TT, Nguyen MN, Tran-Nguyen TS, Huynh CT, Ha QT, Nguyen HN, Tran LS
Cancer Immunology, Immunotherapy : CII 2025
Deep Clustering-Based Immunotherapy Prediction for Gastric Cancer mRNA Vaccine Development
Lan H, Zhao J, Yuan L, Li M, Pu X, Guo Y
International Journal of Molecular Sciences 2025
Assessment of antigen immunogenicity formulated in minigenes transfected into antigen-presenting cells
Villota-Alava MA, Alfaro-Marenco MA, Clavijo-Ramírez CA, Patarroyo MA, Parra-López CA
PLOS One 2025
Immunophenotyping of colon cancer for identification of potential antigens for colon cancer vaccines
Wang X, Lai J, Wang D, Wei K, Yang J
Frontiers in Oncology 2025
Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation
Naffaa MM, Al-Ewaidat OA, Gogia S, Begiashvili V
Exploration of Targeted Anti-tumor Therapy 2025
Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and β-elemene combination therapy.
Zhu Q, Yu C, Chen Y, Luo W, Li M, Zou J, Xiao F, An S, Saiding Q, Tao W, Kong N, Xie T
Proceedings of the National Academy of Sciences of the United States of America 2025
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.
Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh M, Nabavi N, Sethi G, Zhao P, Liu S
Molecular cancer 2025
Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus.
Wang C, Shi Y, Zhang D, Sun Y, Xie J, Wu B, Zhang C, Liu X
EMBO molecular medicine 2025
Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines
Hushmandi K, Imani Fooladi AA, Reiter RJ, Farahani N, Liang L, Aref AR, Nabavi N, Alimohammadi M, Liu L, Sethi G
Experimental Hematology & Oncology 2025
Immune Evasion in Cancer Metastasis: An Unappreciated Role of Monocytes
Patysheva MR, Fedorenko AA, Khozyainova AA, Denisov EV, Gerashchenko TS
Cancers 2025
Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle
Skerritt JH
Vaccines 2025
Neoantigen-targeted dendritic cell vaccine generates long-lived T cell responses exhibiting the full spectrum of differentiation states in lung cancer patients
Joline Ingels, Laurenz Cock, Dieter Stevens, Rupert Mayer, Fabien Théry, Guillem S. Sanchez, David Vermijlen, Karin Weening, Saskia De Smet, Nele Lootens, Marieke Brusseel, Tasja Verstraete, Jolien Buyle, Eva Van Houtte, Pam Devreker, Kelly Heyns, Stijn Munter, Sandra Lint, Glenn Goetgeluk, Sarah Bonte, Lore Billiet, Melissa Pille, Hanne Jansen, Eva Pascal, Lucas Deseins, Lies Vantomme, Maarten Verdonckt, Ria Roelandt, Thomas Eekhout, Niels Vandamme, Georges Leclercq, Tom Taghon, Tessa Kerre, Floris Vanommeslaeghe, Annemieke Dhondt, Liesbeth Ferdinande, Jo Van Dorpe, Liesbeth Desender, Frederic De Ryck, Frank Vermassen, Veerle Surmont, Francis Impens, Björn Menten, Karim Vermaelen, Bart Vandekerckhove
Cell reports. Medicine 2024
NeoMUST: an accurate and efficient multi-task learning model for neoantigen presentation
Ma W, Zhang J, Yao H
Life science alliance 2024
A large-scale study of peptide features defining immunogenicity of cancer neo-epitopes
Wan YT, Koşaloğlu\u2010Yalçın Z, Peters B, Nielsen M
2024
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies
Aparicio B, Theunissen P, Hervas-Stubbs S, Fortes P, Sarobe P
Human Vaccines & Immunotherapeutics 2024
Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy
Shebbo S, Binothman N, Darwaish M, Niaz HA, Abdulal RH, Borjac J, Hashem AM, Mahmoud AB
Frontiers in immunology 2024
A Thermosensitive Bi-Adjuvant Hydrogel Triggers Epitope Spreading to Promote the Anti-Tumor Efficacy of Frameshift Neoantigens.
Ke Y, Xin K, Tao Y, Li L, Chen A, Shao J, Zhu J, Zhang D, Cen L, Chu Y, Yu L, Liu B, Liu Q
2024
Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy.
Eskandari A, Leow TC, Rahman MBA, Oslan SN
Molecular Biotechnology 2024
Birinapant Reshapes the Tumor Immunopeptidome and Enhances Antigen Presentation.
Zhang W, Sun S, Zhu W, Meng D, Hu W, Yang S, Gao M, Yao P, Wang Y, Wang Q, Ji J
International journal of molecular sciences 2024
Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment.
Huang X, Zhu X, Yang H, Li Q, Gai L, Sui X, Lu H, Feng J
Molecules (Basel, Switzerland) 2024
Identification of Lower Grade Glioma Antigens Based on Ferroptosis Status for mRNA Vaccine Development.
Zhao Z, Xing N, Guo H, Li J, Sun G
Pharmacogenomics and Personalized Medicine 2024
AutoEpiCollect, a Novel Machine Learning-Based GUI Software for Vaccine Design: Application to Pan-Cancer Vaccine Design Targeting PIK3CA Neoantigens
Samudrala M, Dhaveji S, Savsani K, Dakshanamurthy S
Bioengineering 2024
NeoAgDT: optimization of personal neoantigen vaccine composition by digital twin simulation of a cancer cell population.
Mösch A, Grazioli F, Machart P, Malone B
Bioinformatics (Oxford, England) 2024
A Review of Clinical Trials of Cancer and Its Treatment as a Vaccine.
Chandarana C, Tiwari A
Reviews on Recent Clinical Trials 2024
Cancer mRNA vaccines: clinical advances and future opportunities.
Sayour EJ, Boczkowski D, Mitchell DA, Nair SK
Nature reviews. Clinical oncology 2024
Refined analytical pipeline for the pharmacodynamic assessment of T-cell responses to vaccine antigens.
Pavlidis MA, Viborg N, Lausen M, Rønø B, Kleine-Kohlbrecher D
Frontiers in immunology 2024
Antigen-Clustered Nanovaccine Achieves Long-Term Tumor Remission by Promoting B/CD 4 T Cell Crosstalk.
Li C, Clauson R, Bugada LF, Ke F, He B, Yu Z, Chen H, Jacobovitz B, Hu H, Chuikov P, Hill BD, Rizvi SM, Song Y, Sun K, Axenov P, Huynh D, Wang X, Garmire L, Lei YL, Grigorova I, Wen F, Cascalho M, Gao W, Sun D
ACS Nano 2024
Empowering standardization of cancer vaccines through ontology: enhanced modeling and data analysis
Zheng J, Li X, Masci AM, Kahn H, Huffman A, Asfaw E, Pan Y, Guo J, He V, Song J, Seleznev AI, Lin AY, He Y
Journal of Biomedical Semantics 2024
Leveraging high-throughput screening technologies in targeted mRNA delivery
Zhang Y, Gao Z, Yang X, Xu Q, Lu Y
Materials today. Bio 2024
mRNA vaccine development and applications: A special focus on tumors (Review)
Chen B, Yang Y, Wang X, Yang W, Lu Y, Wang D, Zhuo E, Tang Y, Su J, Tang G, Shao S, Gu K
International journal of oncology 2024
Exploring treatment options in cancer: Tumor treatment strategies
Liu B, Zhou H, Tan L, Siu KT, Guan XY
Signal Transduction and Targeted Therapy 2024
Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens
Hao Q, Long Y, Yang Y, Deng Y, Ding Z, Yang L, Shu Y, Xu H
Human vaccines 2024
Neoantigens in cancer immunotherapy: focusing on alternative splicing
Huang P, Wen F, Tuerhong N, Yang Y, Li Q
Frontiers in immunology 2024
Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer?
Tadic S, Martínez A
Frontiers in immunology 2024
Tumor Neoepitope-Based Vaccines: A Scoping Review on Current Predictive Computational Strategies
Rocha LG, Guimarães PA, Carvalho MG, Ruiz JC
Vaccines 2024
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
Gao Y, Yang L, Li Z, Peng X, Li H
Biomarker Research 2024
Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors
Wang X, Wang W, Zou S, Xu Z, Cao D, Zhang S, Wei M, Zhan Q, Wen C, Li F, Chen H, Fu D, Jiang L, Zhao M, Shen B
Cell Research 2024
Nanomedicine-based cancer immunotherapy: a bibliometric analysis of research progress and prospects.
Chen C, Yuan P, Zhang Z
Frontiers in immunology 2024
Transformers meets neoantigen detection: a systematic literature review.
Machaca V, Goyzueta V, Cruz MG, Sejje E, Pilco LM, López J, Túpac Y
Journal of integrative bioinformatics 2024
mRNA-based therapeutic strategies for cancer treatment
Taibi T, Cheon S, Perna F, Vu LP
Molecular Therapy 2024
Strategies to Overcome Hurdles in Cancer Immunotherapy.
Kim J, Lee BJ, Moon S, Lee H, Lee J, Kim BS, Jung K, Seo H, Chung Y
Biomaterials research 2024
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
Haque MA, Shrestha A, Mikelis CM, Mattheolabakis G
International Journal of Pharmaceutics: X 2024
Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations
Phan T, Fan D, Melstrom LG
Current Oncology 2024
Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens.
Chi WY, Hu Y, Huang HC, Kuo HH, Lin SH, Kuo CJ, Tao J, Fan D, Huang YM, Wu AA, Hung CF, Wu TC
Journal of biomedical science 2024
Advances and applications of RNA vaccines in tumor treatment.
Yang R, Cui J
Molecular cancer 2024
Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity
Fan T, Xu C, Wu J, Cai Y, Cao W, Shen H, Zhang M, Zhu H, Yang J, Zhu Z, Ma X, Ren J, Huang L, Li Q, Tang Y, Yu B, Chen C, Xu M, Wang Q, Xu Z, Chen F, Liang S, Zhong Z, Jamroze A, Tang DG, Li H, Dong C
Science Advances 2024
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy
Chen J, Duan Y, Che J, Zhu J
Cancer Communications 2024
Potential tumor-specific antigens and immune landscapes identification for mRNA vaccine in thyroid cancer
Wang X, Wang G, Xu Q, Li Y, Song W, Liu Z, Tian Y, Wang L, Zhao K, Wang Y
Frontiers in Oncology 2024
Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment.
Baharom F, Hermans D, Delamarre L, Seder RA
Nature reviews. Immunology 2024
Cancer immunotherapy of Wilms tumor: a narrative review.
He YL, Liu JY, Almgrami RT, Fan YZ, Zhang Y
Future oncology (London, England) 2024
mRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity.
Kenney LL, Chiu RS, Dutra MN, Wactor A, Honan C, Shelerud L, Corrigan JJ, Yu K, Ferrari JD, Jeffrey KL, Huang E, Stein PL
Cell reports. Medicine 2024
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap.
Jonker AH, Tataru EA, Graessner H, Dimmock D, Jaffe A, Baynam G, Davies J, Mitkus S, Iliach O, Horgan R, Augustine EF, Bateman-House A, Pasmooij AMG, Yu T, Synofzik M, Douville J, Lapteva L, Brooks PJ, O'Connor D, Aartsma-Rus A
Nature reviews. Drug discovery 2024
Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies.
Zhu C, Liao JY, Liu YY, Chen ZY, Chang RZ, Chen XP, Zhang BX, Liang JN
Molecular cancer 2024
Immune Checkpoint Inhibitors and Vaccination: Assessing Safety, Efficacy, and Synergistic Potential
New J, Shenton L, Ksayer R, Wang J, Zakharia K, Nicholson LJ, Pandey AC
Vaccines 2024
Advances in mRNA LNP-Based Cancer Vaccines: Mechanisms, Formulation Aspects, Challenges, and Future Directions
Ramadan E, Ahmed A, Naguib YW
Journal of Personalized Medicine 2024
A Cap-Optimized mRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against Mycobacterium tuberculosis
Kozlova A, Pateev I, Shepelkova G, Vasileva O, Zakharova N, Yeremeev V, Ivanov R, Reshetnikov V
Vaccines 2024
Depletion of regulatory T cells enhances the T cell response induced by the neoantigen vaccine with weak immunogenicity
Huang R, Zhou Q, Liu J, Xia Y, Jiao Y, Zhao B, Feng T, Zhou H, Song X, Qin H, Wang J, Cheng L, Ning Y, Sun Q, Liu Y, Su X, Dong Y, Zhang W
Neoplasia (New York, N.Y.) 2024
Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy
Laila UE, An W, Xu ZX
Frontiers in Immunology 2024
Advances and prospects of precision nanomedicine in personalized tumor theranostics
Mao Y, Xie J, Yang F, Luo Y, Du J, Xiang H
Frontiers in Cell and Developmental Biology 2024
mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
Shariati A, Khani P, Nasri F, Afkhami H, Khezrpour A, Kamrani S, Shariati F, Alavimanesh S, Modarressi MH
Biomarker Research 2024
Cross-talk between cuproptosis and ferroptosis to identify immune landscape in cervical cancer for mRNA vaccines development
Zhang X, Xu W, Wang Z, Liu J, Gong H, Zou W
European Journal of Medical Research 2024
Diagnostic and Therapeutic Advances of RNAs in Precision Medicine of Gastrointestinal Tumors
Liu R, Zhou J, Chen X, Zhang J, Chen Q, Liu X, Yao K
Biomedicines 2024
Lipid Nanoparticles Elicit Reactogenicity and Sickness Behavior in Mice via Toll-Like Receptor 4 and Myeloid Differentiation Protein 88 Axis
Korzun T, Moses AS, Jozic A, Grigoriev V, Newton S, Kim J, Diba P, Sattler A, Levasseur PR, Le N, Singh P, Sharma KS, Goo YT, Mamnoon B, Raitmayr C, Souza AP, Taratula OR, Sahay G, Taratula O, Marks DL
ACS nano 2024
Pan-cancer proteogenomics expands the landscape of therapeutic targets
Savage SR, Yi X, Lei JT, Wen B, Zhao H, Liao Y, Jaehnig EJ, Somes LK, Shafer PW, Lee TD, Fu Z, Dou Y, Shi Z, Gao D, Hoyos V, Gao Q, Zhang B
Cell 2024
Neoantigens: promising targets for cancer therapy
Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L
Signal Transduction and Targeted Therapy 2023
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
Yuan Y, Gao F, Chang Y, Zhao Q, He X
Biomarker Research 2023
Research progress on circular RNA vaccines
Bai Y, Liu D, He Q, Liu J, Mao Q, Liang Z
Frontiers in immunology 2023
Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines
Hannani D, Leplus E, Laulagnier K, Chaperot L, Plumas J
Genes & cancer 2023
RNA modification in mRNA cancer vaccines
Mei Y, Wang X
Clinical and Experimental Medicine 2023
Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans
Kuoch H, Krotova K, Graham ML, Brantly ML, Aslanidi G
Biomedicines 2023
mRNA-Based Therapeutics in Cancer Treatment
Sun H, Zhang Y, Wang G, Yang W, Xu Y
Pharmaceutics 2023
Designing neoantigen cancer vaccines, trials, and outcomes
Biswas N, Chakrabarti S, Padul V, Jones LD, Ashili S
Frontiers in immunology 2023
Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
Lam KK, Wong SH, Cheah PY
Cells 2023
Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer.
Yu YJ, Shan N, Li LY, Zhu YS, Lin LM, Mao CC, Hu TT, Xue XY, Su XP, Shen X, Cai ZZ
Cancer Immunology, Immunotherapy 2023
LRP2 and DOCK8 Are Potential Antigens for mRNA Vaccine Development in Immunologically 'Cold' KIRC Tumours.
Zhang S, Xia K, Chang Y, Wei Y, Xiong Y, Tang F, Peng J, Ouyang Y
Human vaccines 2023
Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines.
Aguilar-Gurrieri C, Barajas A, Rovirosa C, Ortiz R, Urrea V, de la Iglesia N, Clotet B, Blanco J, Carrillo J
Cancer Immunology, Immunotherapy 2023
Current Trends in Neoantigen-Based Cancer Vaccines.
Ho SY, Chang CM, Liao HN, Chou WH, Guo CL, Yen Y, Nakamura Y, Chang WC
Pharmaceuticals (Basel, Switzerland) 2023
In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer
Lu L, Ma W, Johnson CH, Khan SA, Irwin ML, Pusztai L
Vaccine 2023
Tissue-resident memory T cells in gastrointestinal tumors: turning immune desert into immune oasis.
Liang M, Wang X, Cai D, Guan W, Shen X
Frontiers in immunology 2023
Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches.
Huang R, Zhao B, Hu S, Zhang Q, Su X, Zhang W
Biomarker Research 2023
mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
Xu Z, Fisher DE
Frontiers in immunology 2023
Nanomaterials for mRNA‐based therapeutics: Challenges and opportunities
Li D, Liu Q, Yang M, Xu H, Zhu M, Zhang Y, Xu J, Tian C, Yao J, Wang L, Liang Y
Bioengineering & Translational Medicine 2023
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen C, Liu X, Chang CY, Wang HY, Wang RF
Genes & development 2023
Transcriptome analysis reveals tumor antigen and immune subtypes of melanoma
XIE J, OU M, YU P, WU D, TANG Q, CAO Y, HANG J, YIN L, XIANG T, WANG M, SHI J
Oncology research 2023
Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma
GE W, SONG S, QI X, CHEN F, CHE X, SUN Y, WANG J, LI X, LIU N, WANG Q, WU G
Oncology research 2023
Vaccinating against cancer: getting to prime time
Chang R, Gulley JL, Fong L
Journal for ImmunoTherapy of Cancer 2023
ISG20 stimulates anti-tumor immunity via a double-stranded RNA-induced interferon response in ovarian cancer
Chen Z, Yin M, Jia H, Chen Q, Zhang H
Frontiers in immunology 2023
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
Han G, Noh D, Lee H, Lee S, Kim S, Yoon HY, Lee SH
Advanced Drug Delivery Reviews 2023
Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment.
Tabasi H, Mollazadeh S, Fazeli E, Abnus K, Taghdisi SM, Ramezani M, Alibolandi M
Applied Biochemistry and Biotechnology 2023
The landscape of T cell antigens for cancer immunotherapy.
Peri A, Salomon N, Wolf Y, Kreiter S, Diken M, Samuels Y
Nature cancer 2023
Tumor neoantigens: Novel strategies for application of cancer immunotherapy
GUAN H, WU Y, LI L, YANG Y, QIU S, ZHAO Z, CHU X, HE J, CHEN Z, ZHANG Y, DING H, PAN J, PAN Y
Oncology research 2023
Emerging Progress of RNA-Based Antitumor Therapeutics
Fu J, Dong H, Wu J, Jin Y
International journal of biological sciences 2023
The use of RNA-based treatments in the field of cancer immunotherapy.
Chehelgerdi M, Chehelgerdi M
Molecular Cancer 2023
Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
Hu C, Liu M, Li Y, Zhao Y, Sharma A, Liu H, Schmidt-Wolf IG
Frontiers in immunology 2023
Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta‐analysis
Zhang T, Xu H, Zheng X, Xiong X, Zhang S, Yi X, Li J, Wei Q, Ai J
2023
mRNA-based cancer therapeutics.
Liu C, Shi Q, Huang X, Koo S, Kong N, Tao W
Nature reviews. Cancer 2023
Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
Mestrallet G, Brown M, Bozkus CC, Bhardwaj N
Frontiers in immunology 2023
Cancer Vaccines: From the State of the Art to the Most Promising Frontiers in the Treatment of Colorectal Cancer
Martinis E, Ricci C, Trevisan C, Tomadini G, Tonon S
Pharmaceutics 2023
A Nanovaccine Based on Adjuvant Peptide FK‐13 and l‐Phenylalanine Poly(ester amide) Enhances CD8+ T Cell‐Mediated Antitumor Immunity
Xie C, You X, Zhang H, Li J, Wang L, Liu Y, Wang Z, Yao R, Tong T, Li M, Wang X, Cui L, Zhang H, Guo H, Li C, Wu J, Xia X
Advanced Science 2023
Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects.
Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D
Nature reviews. Clinical oncology 2023
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
Li J, Xiao Z, Wang D, Jia L, Nie S, Zeng X, Hu W
Molecular Cancer 2023
From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics.
Korzun T, Moses AS, Diba P, Sattler AL, Taratula OR, Sahay G, Taratula O, Marks DL
Pharmaceuticals (Basel, Switzerland) 2023
Small molecular inhibitors for KRAS-mutant cancers
Wu X, Song W, Cheng C, Liu Z, Li X, Cui Y, Gao Y, Li D
Frontiers in immunology 2023
Circular RNA vaccine in disease prevention and treatment.
Niu D, Wu Y, Lian J
Signal Transduction and Targeted Therapy 2023
Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review
Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, Mackiewicz A
Cells 2023
mRNA vaccines in disease prevention and treatment
Zhang G, Tang T, Chen Y, Huang X, Liang T
Signal Transduction and Targeted Therapy 2023
The future of affordable cancer immunotherapy
Schaft N, Dörrie J, Schuler G, Schuler-Thurner B, Sallam H, Klein S, Eisenberg G, Frankenburg S, Lotem M, Khatib A
Frontiers in immunology 2023
Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities
Wang B, Pei J, Xu S, Liu J, Yu J
Frontiers in immunology 2023
Advances in Vaccine Development for Cancer Prevention and Treatment in Lynch Syndrome
Bolivar AM, Dugazac F, Sinha KM, Vilar E
Molecular Aspects of Medicine 2023
Updated Considerations for the Immunopharmacological Aspects of the “Talented mRNA Vaccines”
Perrotta C, Fenizia C, Carnovale C, Pozzi M, Trabattoni D, Cervia D, Clementi E
Human vaccines 2023
Development of a Modular NTA:His Tag Viral Vaccine for Co-delivery of Antigen and Adjuvant
Chung YH, Volckaert BA, Steinmetz NF
Bioconjugate Chemistry 2023
Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy
Shim K, Jo H, Jeoung D
International journal of molecular sciences 2023
Advances in mRNA-Based Cancer Vaccines
Ni L
Human vaccines 2023
Challenges in developing personalized neoantigen cancer vaccines.
Katsikis PD, Ishii KJ, Schliehe C
Nature reviews. Immunology 2023
Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses
Jayaraman S, Montagne JM, Nirschl TR, Marcisak E, Johnson J, Huff A, Hsiao MH, Nauroth J, Heumann T, Zarif JC, Jaffee EM, Azad N, Fertig EJ, Zaidi N, Larman HB
2023
Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment
Tockary TA, Abbasi S, Matsui-Masai M, Hayashi A, Yoshinaga N, Boonstra E, Wang Z, Fukushima S, Kataoka K, Uchida S
Proceedings of the National Academy of Sciences 2023
Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines
Lin F, Lin EZ, Anekoji M, Ichim TE, Hu J, Marincola FM, Jones LD, Kesari S, Ashili S
Journal of Translational Medicine 2023
Current status of vaccine immunotherapy for gastrointestinal cancers.
Suzuki N, Shindo Y, Nakajima M, Tsunedomi R, Nagano H
Surgery Today 2023
Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines
Hargrave A, Mustafa AS, Hanif A, Tunio JH, Hanif SN
Human vaccines 2023
Therapeutic cancer vaccines: advancements, challenges, and prospects.
Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C
Signal Transduction and Targeted Therapy 2023
Research progress on the immune microenvironment and immunotherapy in gastric cancer
Mou P, Ge QH, Sheng R, Zhu TF, Liu Y, Ding K
Frontiers in immunology 2023
Colorectal Cancer Immunotherapy: State of the Art and Future Directions.
Cornista AM, Giolito MV, Baker K, Hazime H, Dufait I, Datta J, Khumukcham SS, De Ridder M, Roper J, Abreu MT, Breckpot K, Van der Jeught K
2023
Cancer vaccines: from an immunology perspective.
Makker S, Galley C, Bennett CL
2023
mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer.
Malla R, Srilatha M, Farran B, Nagaraju GP
Molecular Therapy 2023
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment.
Han R, Wang Y, Lu L
Pharmaceutics 2023
Combinatorial development of nebulized mRNA delivery formulations for the lungs
Jiang AY, Witten J, Raji IO, Eweje F, MacIsaac C, Meng S, Oladimeji FA, Hu Y, Manan RS, Langer R, Anderson DG
Nature Nanotechnology 2023
Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes
Bowen CM, Sinha KM, Vilar E
Clinics in colon and rectal surgery 2023
Neoantigen cancer vaccines: a new star on the horizon
Li X, You J, Hong L, Liu W, Guo P, Hao X
Cancer biology & medicine 2023
Challenges and solutions for therapeutic TCR-based agents.
Malviya M, Aretz ZEH, Molvi Z, Lee J, Pierre S, Wallisch P, Dao T, Scheinberg DA
Immunological Reviews 2023
Advances in Non-Viral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy
Neill B, Romero AR, Fenton OS
ACS applied bio materials 2023
Messenger RNA Vaccines for Cancer Immunotherapy: Progress Promotes Promise
Amanda L. Huff, Elizabeth Jaffee, Neeha Zaidi
Journal of Clinical Investigation 2022
Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy
M Okada, K Shimizu, S Fujii
International journal of molecular sciences 2022
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
J Liu, M Fu, M Wang, D Wan, Y Wei, X Wei
Journal of Hematology & Oncology 2022
mRNA cancer vaccines: Advances, trends and challenges
Q He, H Gao, D Tan, H Zhang, J Wang
Acta pharmaceutica Sinica. B 2022
The role of biomarkers in personalized immunotherapy
K Sankar, J Ye, Z Li, L Zheng, W Song, S Hu-Lieskovan
Biomarker Research 2022
Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers
S Pao, M Chu, S Hung
Pharmaceutics 2022
Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
E Salvatori, L Lione, M Compagnone, E Pinto, A Conforti, G Ciliberto, L Aurisicchio, F Palombo
npj Vaccines 2022
Neoantigens and their potential applications in tumor immunotherapy (Review)
X Fang, Z Guo, J Liang, J Wen, Y Liu, X Guan, H Li
Oncology Letters 2022
Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies
C Reynolds, S Tran, M Jain, A Narendran
Human vaccines 2022
Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development
H Lin, K Wang, Y Xiong, L Zhou, Y Yang, S Chen, P Xu, Y Zhou, R Mao, G Lv, P Wang, D Zhou
Frontiers in immunology 2022
What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination
A Redwood, I Dick, J Creaney, B Robinson
OncoImmunology 2022
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines
S Tahtinen, A Tong, P Himmels, J Oh, A Paler-Martinez, L Kim, S Wichner, Y Oei, M McCarron, E Freund, Z Amir, C de la Cruz, B Haley, C Blanchette, J Schartner, W Ye, M Yadav, U Sahin, L Delamarre, I Mellman
Nature Immunology 2022
mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic
P Chen, X Shi, W He, G Zhong, Y Tang, H Wang, P Zhang
Human Vaccines & Immunotherapeutics 2022
mRNA vaccines: the most recent clinical applications of synthetic mRNA
S Kwon, M Kwon, S Im, K Lee, H Lee
Archives of Pharmacal Research 2022
The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers
K Anderson, T Erick, M Chen, H Daley, M Campbell, Y Colson, M Mihm, L Zakka, M Hopper, W Barry, E Winer, G Dranoff, B Overmoyer
Breast Cancer Research and Treatment 2022
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
J Wei, A Hui
Cancer Treatment Reviews 2022
mRNA-based therapeutics: powerful and versatile tools to combat diseases
S Qin, X Tang, Y Chen, K Chen, N Fan, W Xiao, Q Zheng, G Li, Y Teng, M Wu, X Song
Signal Transduction and Targeted Therapy 2022
Advances in mRNA vaccines
Li M, Wang Z, Xie C, Xia X
International review of cell and molecular biology 2022
Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity
Hernandez R, Malek TR
Frontiers in Oncology 2022
Protective Immune Responses Induced by an mRNA-LNP Vaccine Encoding prM-E Proteins against Japanese Encephalitis Virus Infection
Chen T, Zhu S, Wei N, Zhao Z, Niu J, Si Y, Cao S, Ye J
Viruses 2022
Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development
Chen Z, Wang X, Yan Z, Zhang M
Cancer Medicine 2022
The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
Ladak RJ, He AJ, Huang YH, Ding Y
Frontiers in immunology 2022
Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development
Lu T, Xu R, Wang CH, Zhao JY, Peng B, Wang J, Zhang LY
Frontiers in Genetics 2022
mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells
Bevers S, Kooijmans SA, Van de Velde E, Evers MJ, Seghers S, Gitz-Francois JJ, van Kronenburg NC, Fens MH, Mastrobattista E, Hassler L, Sork H, Lehto T, Ahmed KE, El Andaloussi S, Fiedler K, Breckpot K, Maes M, Van Hoorick D, Bastogne T, Schiffelers RM, De Koker S
Molecular Therapy 2022
Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer
Jin X, Liu Z, Yang D, Yin K, Chang X
Frontiers in immunology 2022
Neoantigens and NK Cells: “Trick or Treat” the Cancers?
Lv D, Khawar MB, Liang Z, Gao Y, Sun H
Frontiers in immunology 2022
Identification of Tumor Antigens and Immune Subtypes in Lung Adenocarcinoma for mRNA Vaccine Development
Xu R, Lu T, Zhao J, Wang J, Peng B, Zhang L
Frontiers in Cell and Developmental Biology 2022
Absolute Lymphocyte Count After COVID-19 Vaccination Is Associated with Vaccine-Induced Hypermetabolic Lymph Nodes on 18F-FDG PET/CT: A Focus in Breast Cancer Care
Seban RD, Richard C, Nascimento-Leite C, Ghidaglia J, Provost C, Gonin J, Tourneau CL, Romano E, Deleval N, Champion L
Journal of Nuclear Medicine 2022
Application of lipid-based nanoparticles in cancer immunotherapy
Zhang Z, Yao S, Hu Y, Zhao X, Lee RJ
Frontiers in immunology 2022
Cancer vaccines: the next immunotherapy frontier.
Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, Brody JD
2022
mRNA vaccines in the prevention and treatment of diseases
Gu Y, Duan J, Yang N, Yang Y, Zhao X
2022
Neoantigens in precision cancer immunotherapy: from identification to clinical applications
Zhang Q, Jia Q, Zhang J, Zhu B
Chinese Medical Journal 2022
RNA therapeutics: updates and future potential.
Zhang C, Zhang B
Science China Life Sciences 2022
Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects.
Huang T, Peng L, Han Y, Wang D, He X, Wang J, Ou C
Frontiers in immunology 2022
mRNA vaccines: Past, present, future.
Karam M, Daoud G
Asian Journal of Pharmaceutical Sciences 2022
A synthetic DNA template for fast manufacturing of versatile single epitope mRNA
de Mey W, De Schrijver P, Autaers D, Pfitzer L, Fant B, Locy H, Esprit A, Lybaert L, Bogaert C, Verdonck M, Thielemans K, Breckpot K, Franceschini L
2022
Neoantigens and their clinical applications in human gastrointestinal cancers.
Eshkiki ZS, Agah S, Tabaeian SP, Sedaghat M, Dana F, Talebi A, Akbari A
World journal of surgical oncology 2022
Clinical advances and ongoing trials on mRNA vaccines for cancer treatment
Lorentzen CL, Haanen JB, Met Ö, Svane IM
The Lancet Oncology 2022
Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development
Li RQ, Wang W, Yan L, Song LY, Guan X, Zhang W, Lian J
Frontiers in Oncology 2022
Identification of tumor antigens and immune subtypes in lung squamous cell carcinoma for mRNA vaccine development
Zhao J, Xu R, Lu T, Wang J, Zhang L
Journal of Thoracic Disease 2022
Engineering neoantigen vaccines to improve cancer personalized immunotherapy
Liu Z, Lv J, Dang Q, Liu L, Weng S, Wang L, Zhou Z, Kong Y, Li H, Han Y, Han X
International journal of biological sciences 2022
Integrative insights and clinical applications of single-cell sequencing in cancer immunotherapy.
Liu Z, Li H, Dang Q, Weng S, Duo M, Lv J, Han X
Cellular and molecular life sciences : CMLS 2022
Editorial overview: Vaccines: Reinvigorating therapeutic cancer vaccines.
Robles-Oteiza C, Wu CJ
Current Opinion in Immunology 2022
Oncology and cardiology positron emission tomography/computed tomography faced with COVID-19: A review of available literature data.
Minamimoto R
Frontiers in Medicine 2022
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
Zhou W, Yu J, Li Y, Wang K
Experimental Hematology and Oncology 2022
Identification of tumor antigens and immunogenic cell death-related subtypes for the improvement of immunotherapy of breast cancer
Cao X, Zhou X, Chen C, Wang Z, Sun Q
Frontiers in Cell and Developmental Biology 2022
Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment
Karim ME, Haque ST, Al-Busaidi H, Bakhtiar A, Tha KK, Holl MM, Chowdhury EH
Archives of Pharmacal Research 2022
The role of noncoding RNAs in cancer lipid metabolism
Wang Y, Li Q, Wang S, Wang BJ, Jin Y, Hu H, Fu QS, Wang JW, Wu Q, Qian L, Cao TT, Xia YB, Huang XX, Xu L
Frontiers in Oncology 2022
Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics
Yang W, Cao J, Cheng H, Chen L, Yu M, Chen Y, Cui X
Bioactive Materials 2022
Current progress in the development of prophylactic and therapeutic vaccines.
Li T, Qian C, Gu Y, Zhang J, Li S, Xia N
Science China Life Sciences 2022
Identifying tumor antigens and immuno‐subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine
Tan H, Yu T, Liu C, Wang Y, Jing F, Ding Z, Liu J, Shi H
Cancer Medicine 2022
Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells
Thelen M, Keller D, Lehmann J, Wennhold K, Weitz H, Bauer E, Gathof B, Brüggemann M, Kotrova M, Quaas A, Mallmann C, Chon SH, Hillmer AM, Bruns C, von Bergwelt-Baildon M, Garcia-Marquez MA, Schlößer HA
Journal for ImmunoTherapy of Cancer 2022
Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines
Li J, Wu Y, Xiang J, Wang H, Zhuang Q, Wei T, Cao Z, Gu Q, Liu Z, Peng R
Chemical Engineering Journal 2022
Third-Generation Vaccines: Features of Nucleic Acid Vaccines and Strategies to Improve Their Efficiency.
Melo ARDS, de Macêdo LS, Invenção MDCV, de Moura IA, da Gama MATM, de Melo CML, Silva AJD, Batista MVA, Freitas AC
Genes & development 2022
Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises
Ashi MO, Mami-Chouaib F, Corgnac S
2022
Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma
Li HX, Liu TR, Tu ZX, Xie CB, Wen WP, Sun W
Biomolecules 2022
Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic
Fenton GA, Mitchell DA
Clinical cancer research 2022
Clinical Development of mRNA Vaccines: Challenges and Opportunities.
August A, Brito L, Paris R, Zaks T
Current topics in microbiology and immunology 2022
Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases.
Chung S, Lee CM, Zhang M
2022
Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development
X Huang, T Tang, G Zhang, T Liang
Molecular Cancer 2021
mRNA therapeutics in cancer immunotherapy
JD Beck, D Reidenbach, N Salomon, U Sahin, Ö Türeci, M Vormehr, LM Kranz
Molecular Cancer 2021
Promising Technologies in the Field of Helminth Vaccines
DJ Perera, M Ndao
Frontiers in immunology 2021
Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma
Z Wang, L Ran, C Chen, R Shi, Y Dong, Y Li, X Zhou, Y Qi, P Zhu, Y Gao, Y Wu
Human vaccines 2021
Targeting KRAS in pancreatic cancer: new drugs on the horizon
SF Bannoura, H Uddin, M Nagasaka, F Fazili, MN Al-Hallak, PA Philip, B El-Rayes, AS Azmi
Cancer and Metastasis Reviews 2021
Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
M Saillard, M Cenerenti, P Romero, C Jandus
Human vaccines 2021
Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
LF Hu, HR Lan, D Huang, XM Li, KT Jin
Frontiers in Oncology 2021
Ras Isoforms from Lab Benches to Lives—What Are We Missing and How Far Are We?
A Nair, KF Kubatzky, B Saha
International journal of molecular sciences 2021
Know thy immune self and non‐self: Proteomics informs on the expanse of self and non‐self, and how and where they arise
S Joyce, N Ternette
PROTEOMICS 2021
Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy
N Levin, BC Paria, NR Vale, R Yossef, FJ Lowery, MR Parkhurst, Z Yu, M Florentin, G Cafri, JJ Gartner, ML Shindorf, LT Ngo, S Ray, SP Kim, AR Copeland, PF Robbins, SA Rosenberg
Clinical cancer research 2021
Mimicking the Biology of Engineered Protein and mRNA Nanoparticle Delivery Using a Versatile Microfluidic Platform
V Palacio-Castañeda, RO Egberink, A Sait, L Andrée, BM Sala, NH Besheli, E Oosterwijk, J Nilvebrant, SC Leeuwenburgh, R Brock, WP Verdurmen
Pharmaceutics 2021
Monitoring T Cells Responses Mounted by Therapeutic Cancer Vaccines
KP Lim, NS Zainal
Frontiers in Molecular Biosciences 2021
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks
JK Hwang, T Zhang, AZ Wang, Z Li
Journal of Hematology & Oncology 2021
High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4 + and CD8 + neoantigen-specific T cells to promote antitumor immunity
R Hernandez, KM LaPorte, S Hsiung, AS Savio, TR Malek
Journal for ImmunoTherapy of Cancer 2021
Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance
NA Nagy, AM de Haas, TB Geijtenbeek, R van Ree, SW Tas, Y van Kooyk, EC de Jong
Frontiers in immunology 2021
Targeting public neoantigens for cancer immunotherapy
AH Pearlman, MS Hwang, MF Konig, EH Hsiue, J Douglass, SR DiNapoli, BJ Mog, C Bettegowda, DM Pardoll, SB Gabelli, N Papadopoulos, KW Kinzler, B Vogelstein, S Zhou
2021
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
P Dillard, N Casey, S Pollmann, P Vernhoff, G Gaudernack, G Kvalheim, S Wälchli, EM Inderberg
OncoImmunology 2021
mRNA vaccine for cancer immunotherapy
L Miao, Y Zhang, L Huang
Molecular Cancer 2021
Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion?
K Manoutcharian, JG Valle, G Gevorkian
Archivum Immunologiae et Therapiae Experimentalis 2021
Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicine—Specific Cancer Targeting with Undetectable Toxicity
DW Binzel, X Li, N Burns, E Khan, WJ Lee, LC Chen, S Ellipilli, W Miles, YS Ho, P Guo
Chemical Reviews 2021
Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design
X Cai, JJ Li, T Liu, O Brian, J Li
Briefings in Functional Genomics 2021
Assessing immune response upon systemic RNA vaccination on [18F]-FDG PET/CT for COVID-19 vaccine and then for immuno-oncology?
RD Seban, L Champion, R Yeh, LH Schwartz, L Dercle
European Journal of Nuclear Medicine and Molecular Imaging 2021
Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines
A Azadi, A Golchini, S Delazar, FA Kahaki, SM Dehnavi, Z Payandeh, S Eyvazi
Biological Procedures Online 2021
Lipid nanoparticles for mRNA delivery
X Hou, T Zaks, R Langer, Y Dong
Nature Reviews Materials 2021
Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human
CL Chiang, R Rovelli, A Sarivalasis, LE Kandalaft
Cancers 2021
TFDP3 as E2F Unique Partner, Has Crucial Roles in Cancer Cells and Testis
J Huang, Y Wang, J Liu, M Chu, Y Wang
Frontiers in Oncology 2021
RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
HM Abdelzaher, AS Gabr, BM Saleh, RM Gawad, AA Nour, A Abdelanser
Human vaccines 2021
Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies
H Zhu, X Liu
Frontiers in Oncology 2021
Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines
Y Wang, H Tan, T Yu, X Chen, F Jing, H Shi
Frontiers in immunology 2021
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination.
Yu AM, Tu MJ
Pharmacology & Therapeutics 2021

← Previous 1 2 3 … 9 10 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 2 news outlets
Blogged by 1
Posted by 100 X users
Referenced in 7 patents
353 readers on Mendeley
See more details